Jefferies reaffirmed its positive stance on Praxis Precision Medicines Inc . (NASDAQ:PRAX), maintaining a Buy rating and a price target of $305.00. The stock, currently valued at $1.54 billion market ...
Truist raised the firm’s price target on Praxis Precision (PRAX) to $175 from $150 and keeps a Buy rating on the shares. The firm is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results